Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Entrectinib como agente único en la terapia inicial para niños

2 de noviembre de 2026 actualizado por: St. Jude Children's Research Hospital

FASE 2 Estudio de entrectinib como agente único en terapia inicial para niños

This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.

Descripción general del estudio

Descripción detallada

PRIMARY OBJECTIVE

  • To determine the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) (Cohort 1).

SECONDARY OBJECTIVES

  • To estimate the 2-year and 5-year progression free survival (PFS) and overall survival (OS) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
  • To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
  • To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused HGG treated who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 1).
  • To describe the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG (Cohort 2).
  • To estimate the 2-year and 5-year PFS and OS in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
  • To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
  • To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 2).
  • To describe toxicities experienced by patients younger than 3 years of age treated with entrectinib (Cohort 1 and 2).
  • To evaluate number of patients that are screened for the study and eligible versus enrolled and treated with entrectinib (Cohort 1 and 2).
  • To measure the time intervals (days) from time of initial diagnostic surgery to screening and enrollment in this study (Cohort 1 and 2).

The trial will have 2 cohorts: Cohort 1: patients diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) and Cohort 2: patients diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG.

Patients receive entrectinib enterally once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients requiring bridging therapy prior to starting entrectinib may receive cyclophosphamide intravenously (IV) over 1 hour on day 1, etoposide IV over 1 hour on day 1 and 2, carboplatin IV over 1 hour on day 2, filgrastim subcutaneously (SC) or IV or pegfilgrastim SC on day 3.

A gross total resection or significant debulking may become possible if a response to entrectinib is seen. If surgical resection is performed and a gross total resection is achieved, 24 cycles of entrectinib will be completed, including those before and after surgery.

After treatment, patients will be followed for 5 years.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

52

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • São Paulo, Brasil, 08270-070
        • Reclutamiento
        • Hospital Santa Marcelina
        • Investigador principal:
          • Sidnei Epelman, MD
        • Contacto:
      • São Paulo, Brasil, 04039-001
        • Reclutamiento
        • GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer)
        • Contacto:
        • Investigador principal:
          • Andrea M. Cappellano, MD
    • São Paulo
      • Barretos, São Paulo, Brasil, 14784400
        • Reclutamiento
        • Hospital de Câncer de Barretos
        • Contacto:
        • Investigador principal:
          • Thais J. Vampre, MD
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38105
        • Reclutamiento
        • St. Jude Children's Research Hospital
        • Contacto:
        • Investigador principal:
          • Daniel Moreira, MD, MEd
        • Contacto:
      • Amman, Jordán, 11941
        • Reclutamiento
        • King Hussein Cancer Center
        • Contacto:
          • Nisreen Amayiri, MD
          • Número de teléfono: 6376 (962 6) 5300460
          • Correo electrónico: namayiri@khcc.jo
        • Investigador principal:
          • Nisreen Amayiri, MD
      • Lima, Perú
        • Reclutamiento
        • Instituto Nacional de Enfermedades Neoplásicas
        • Contacto:
        • Investigador principal:
          • Rosdali Coronado, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

No mayor que 3 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria: Screening Phase

  • Age from birth to age <3 years at the time of diagnosis (date of surgical resection/biopsy)
  • Participant with presumed newly diagnosed tumor in the supratentorial compartment
  • Patient must have measurable disease based on RAPNO criteria
  • ≤84 days since surgery (resection or biopsy)
  • Available tumor tissue for central review
  • Parent/guardian has the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines

Exclusion Criteria: Screening Phase

  • Previous exposure to cytotoxic chemotherapy or radiotherapy

Inclusion Criteria: COHORT 1

  • Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)

  • High-grade glioma (World Health Organization [WHO] grade III or IV) harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

  • Patients must have measurable disease as defined by RAPNO criteria

  • Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

  • ≤28 days since study screening

  • Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

  • Neurologic deficits must have been stable for at least 7 days prior to study enrollment

  • Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

  • Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment)

  • Absolute neutrophil count >1,000/µL

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN)

  • Bilirubin ≤ 1.5 x ULN

  • Adequate renal function as defined by the following age-based serum creatinine concentrations:

    • 0 to <1 year: 0.5 mg/dL
    • 1 to <2 years: 0.6 mg/dL
    • 2 to 3 years: 0.8 mg/dL
  • Adequate cardiac function as defined by electrocardiogram (ECG) with Fridericia's corrected QT interval (QTc) ≤ 450 msec and echocardiogram left ventricular ejection fraction (LVEF) >50%

  • Screening and enrollment consents signed

  • Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures

Inclusion Criteria: COHORT 2

  • Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)

  • CNS tumor other than HGG harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

  • Patients must have measurable disease as defined by RAPNO criteria

  • Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

  • ≤28 days since study screening

  • Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

  • Neurologic deficits must have been stable for at least 7 days prior to study enrollment.

  • Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

  • Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment);

  • Absolute neutrophil count >1,000/µL.

  • ALT and ALT ≤2.5x the upper limit of normal (ULN)

  • Bilirubin ≤ 1.5 x ULN

  • Adequate renal function as defined by the following age-based serum creatinine concentrations:

    • 0 to <1 year: 0.5 mg/dL
    • 1 to <2 years: 0.6 mg/dL
    • 2 to 3 years: 0.8 mg/dL
  • Adequate cardiac function as defined by ECG with QTc ≤ 450 msec and echocardiogram LVEF >50%

  • Screening and enrollment consents signed

  • Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures

Exclusion Criteria: COHORT 1 AND 2

  • Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history
  • History of recent (3 months) symptomatic congestive heart failure
  • Known active, uncontrolled infection (bacterial, fungal, or viral)
  • Receiving enzyme inducing antiepileptic drugs (EIAEDs)
  • Any prior cancer therapy including chemotherapy (excluding Bridging Chemotherapy Cycle), targeted therapy, immunotherapy, cellular therapy, or radiation
  • Receiving another investigational agent concurrently
  • Surgery within 2 weeks prior to treatment enrollment
  • Patients with known hypersensitivity to excipients of the investigational medicinal product
  • Active gastrointestinal disease or malabsorption disorder (e.g. Crohn's disease, ulcerative colitis, short-gut syndrome) that would impair drug absorption
  • Inability to take medication enterally

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Entrectinib therapy, Cohort 1 and Cohort 2

Cohort 1: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) will receive therapy as outline in Detailed Description.

Cohort 2: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG will receive therapy as outline in Detailed Description.

Given IV

Otros nombres:
  • Paraplatin®

Given IV

Otros nombres:
  • VP-16

Given orally (PO) or enterally

Otros nombres:
  • Rozlytrek

Given intravenous (IV)

Otros nombres:
  • Cytoxan®

Given subcutaneous (SQ) or IV

Otros nombres:
  • Filgrastim

Given SQ as part of recommended Bridging Therapy instead of G-CSF.

Otros nombres:
  • Neulasta

A gross total resection or significant debulking may become possible if a response to entrectinib is seen.

Otros nombres:
  • Resección quirúrgica

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall response rate (ORR) (Cohort 1)
Periodo de tiempo: After cycle 4 (each cycle is 28 days).

ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations.

After cycle 4 (each cycle is 28 days).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression free survival (PFS) (Cohort 1)
Periodo de tiempo: At 2 and 5 years

PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method.

At 2 and 5 years
Overall survival (OS) (Cohort 1)
Periodo de tiempo: At 2 and 5 years

OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method.

At 2 and 5 years
Duration of response (DOR) (Cohort 1)
Periodo de tiempo: Up to 5 years

DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time.

Up to 5 years
Patients who have second surgeries (Cohort 1)
Periodo de tiempo: Up to 5 years

Percentage of patients who had second surgeries.

Up to 5 years
Patients who undergo gross-total resection after treatment (Cohort 1)
Periodo de tiempo: Up to 5 years

Percentage of patients who underwent a gross-total resection.

Up to 5 years
ORR (Cohort 2)
Periodo de tiempo: After cycle 4 (each cycle is 28 days).

ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations.

After cycle 4 (each cycle is 28 days).
PFS (Cohort 2)
Periodo de tiempo: At 2 and 5 years

PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method.

At 2 and 5 years
OS (Cohort 2)
Periodo de tiempo: At 2 and 5 years

OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method.

At 2 and 5 years
DOR (Cohort 2)
Periodo de tiempo: Up to 5 years

DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time.

Up to 5 years
Patients who have second surgeries (Cohort 2)
Periodo de tiempo: Up to 5 years

Percentage of patients who had second surgeries. [Time Frame: Up to 5 years]

Up to 5 years
Patients who undergo gross-total resection after treatment (Cohort 2)
Periodo de tiempo: Up to 5 years

Percentage of patients who underwent a gross-total resection.

Up to 5 years
Incidence of adverse events (Cohort 1 and 2)
Periodo de tiempo: Up to 5 years

Percentage of adverse events on therapy including Entrectinib, captured using National Cancer Institute Common Terminology Criteria for Adverse Events 5.0.

Up to 5 years
Number of patients screened versus enrolled and treated (Cohort 1 and 2)
Periodo de tiempo: Up to 5 years

Number of enrolled and treated patients as a percentage of number of patients screened and eligible for study.

Up to 5 years
Time from initial diagnostic surgery to screening and enrollment (Cohort 1 and 2)
Periodo de tiempo: Up to 5 years

Median time in days from initial surgery to screening and enrollment on study.

Up to 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: Daniel Moreira, MD, MEd, St. Jude Children's Research Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de mayo de 2026

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2032

Fechas de registro del estudio

Enviado por primera vez

22 de julio de 2024

Primero enviado que cumplió con los criterios de control de calidad

25 de julio de 2024

Publicado por primera vez (Actual)

30 de julio de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • GLOBOTRK
  • NCI-2024-02977 (Identificador de registro: NCI Clinical Trial Registration Program)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Marco de tiempo para compartir IPD

Data will be made available at the time of article publication.

Criterios de acceso compartido de IPD

Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir